This approval positions Lupin to tap into a substantial market opportunity for a drug indicated for the treatment of Lambert-Eaton myasthenic syndrome (LEMS), a rare autoimmune neuromuscular disorder, the company said in a filing.
Share it
Open an Account in less than 1 Min.
Need help? Call us
+916280171443
Services
Company
Get in touch
- +916280171443
- info@markettrade.live
- Pjazza Mifsud Bonnici, Marsascala, Malta
- 333, Pali Pathar, Khar West, Mumbai, Maharashtra 400052
Copyright © 2025 Marketrade Private Limited